CONFERENCE SERIES: Clinical Trials & Translational Medicine
Recorded at: Bio-IT World Conference & Expo
Digital Course: Utilization of EHRs/EMRs to Further Drug and Disease Related Research
About this Product:
The American Reinvestment and Recovery Act, EHR-incentive rule and ‘Meaningful use objective/measures’ guidelines have the potential to accelerate the utilization of EHR/EMRs by healthcare providers and institutions. Patients, Providers, Manufacturers and Payors are expected to benefit from improved public health decision-support delivered through effective use of this type of evidence. In this digital course, we discuss the potential benefits and risks involved in mining information outside of controlled trials to create insights on diseases, drugs, and patient populations.
SESSION: Retrospective Analysis and Data Mining
How are existing health records used for basic research and clinical trials?
How do you extract useful information from current systems and datasets that have not been designed for research purposes?
What pre-existing data is out there and how do you work with this ‘dirty’ data?
How are data derived from EHRs/EMRs integrated with biological knowledge in the public domain?
SESSION: Prospective Analysis and the Path Forward
What is the future and how do we get there?
How do you build a pilot? What are the key challenges and true costs?
What are the challenges with achieving semantic interoperability with such data?
Where does “meaningful use” fit in?
About this Product:
Over 173 Minutes
Site License: $1380
Agenda At A Glance:
Taking EMR Standards to the Next Level to Support Biopharmaceutical Research
William Hogan, M.D., Associate Professor and Chief, Biomedical Informatics, University of Arkansas for Medical Sciences
At present, biopharmaceutical research based on the electronic medical record (EMR) is not possible on a significant scale. Even if legal, privacy, and regulatory issues were solved, it would remain inhibited by the lack of EMR adoption of standards for disease, drugs, and hypersensitivity conditions, among other things. However, even if EMRs did adopt today's standards, limitations on our ability to leverage EMRs for biopharmaceutical research would remain. A careful analysis of problems in today’s standards reveals solutions that will greatly facilitate biopharmaceutical research if and when adopted.
Biography: Dr. William R. Hogan joined the University of Arkansas for Medical Sciences (UAMS) as its inaugural Chief of the Division of Biomedical Informatics in November 2009. He has research interests in ontology, biosurveillance, diagnosis, and clinical and translational research informatics. Dr. Hogan came to UAMS after >10 years of research and practice of biomedical informatics. He has published over 40 papers on various topics, including data quality, medical vocabularies, ontology, and biosurveillance.
EHR/EMR Data Sources and Data Mining for Drug Safety Research
Zhaohui (John) Cai, Ph.D., Director Biomedical Informatics, Clinical Information Science, AstraZeneca Pharmaceuticals Inc.
Biopharmaceutical companies are realizing the importance of demonstrating comparative effectiveness of their products in real world in addition to obtaining marketing approval through clinical trials. It’s easy to follow this trend by investing in comparative effectiveness research area using EHR/EMR data, without realizing the challenges ahead or having a strategy to meet those challenges. We will start with a basic review of different types of data sources related to EMRs/EHRs, and then focus on pros and cons of different data types and data mining methods for answering drug safety related questions, and finally propose a forward-looking approach to meet the challenges in EHR/EMR data mining by getting the right data for right questions and right people with right experience.
Biography: Zhaohui (John) Cai, MD, PhD is a Director of Biomedical Informatics at AstraZeneca supporting Patient Safety in Clinical Development. He received his MD from China Medical University, PhD from Albany Medical College, and Biomedical Informatics Fellowship training from Harvard Medical School. At AstraZeneca, he is also the US region coordinator of modeling and simulation in Statistics and Informatics. He has been involved in data mining, text mining, as well as providing modeling support to drug projects and safety knowledge groups.
EHR/EMR Data Mining: From Therapeutic Targets to Effective Medicines
Kaushal Desai, Global Informatics Lead for Real World Evidence Program, AstraZeneca Pharmaceuticals Inc
Practice-based evidence from EHR data mining is likely to advance therapeutic targets towards medicines that lead to greater effectiveness and lower healthcare costs. It is widely anticipated that effective utilization of EHR/EMR data will improve the design and interpretation of clinical trials. In this talk, we will discuss the primary drivers for increased adoption of real world evidence in clinical development, followed by specific examples that illustrate potential use cases for this type of evidence across Research and Development. We will end with a discussion on strategies for integration of EHR/EMR data with biological knowledge.
Biography: Kaushal Desai is a Senior Biomedical Informatics Scientist at AstraZeneca Pharmaceuticals, a global innovation-driven integrated biopharmaceutical company. After graduating with dual masters degrees in Biomedical Engineering and Information studies in 2001, he joined AstraZeneca as a data mining and integration expert in Experimental Medicine. Kaushal has led several ontology-driven integration efforts in translational science and clinical development, including the standardization effort for a global data warehouse of gene expression experiments and the design of unification capability for AstraZeneca’s federated repository of molecular target information. In 2006, Kaushal successfully led the design and development of AstraZeneca’s first semantic repository of Clinical Studies. Kaushal’s research interests include semantic repository design, Healthcare and Clinical data mining, in silico safety evaluation and Network Pharmacology. He is currently the Global Biomedical Informatics lead for AstraZeneca’s Real World Evidence (RWE) program.
Meeting Meaningful Use Criteria through Referent Tracking
Werner Ceusters, M.D., Director, Ontology Research Group, NYS Center of Excellence in Bioinformatics & Life Sciences
In order to meet the Meaningful Use requirements, the information models of many electronic health record systems need to be adjusted or work-arounds provided. One can opt for a quick-and-dirty solution that is good enough for the current criteria but perhaps not for additional future demands. A better way however is to introduce a more visionary change that does not depend on specific rules and regulations concerning data management. We will discuss how EHRs and Clinical Research systems that embrace Referent Tracking require only minimal structural changes to accommodate a wide range of possible future demands.
Biography: Dr. Werner Ceusters studied medicine, neuro-psychiatry, informatics and knowledge engineering in Belgium. Since 1993, he has been involved in numerous national and European research projects in the area of Electronic Health Records, Natural Language Understanding and Ontology. He was Executive Director of the European Centre for Ontological Research at Saarland University, Germany. He is currently Professor in the Psychiatry Department of the School of Medicine and Biomedical Sciences, SUNY at Buffalo NY and Director of the Ontology Research Group of the New York State Center of Excellence in Bioinformatics and Life Sciences. His research is focused on the application of Referent Tracking for data management and the requirements of ontologies and terminologies to be useful for annotation under this framework.
Integration of Drug Classification Information with EHR Data for Feasibility Study Cohort Identification
Richard H. Scheuermann, Ph.D., Professor, Department of Pathology, Director, Division of Biomedical Informatics, University of Texas Southwestern Medical Center
Clinical and translational research relies on the availability of sufficient numbers of patients with relevant characteristics to perform the studies described in the research protocol. In order to allow investigators to determine if a new study idea would be feasible given the local patient population, we developed the U.T. Southwestern Clinical Research Information System – Study Feasibility (utCRIS-SF) application. utCRIS-FS includes an i2b2 data warehouse back end containing anonymized patient information derived from our hospital and out patient clinical electronic health records (EHR) systems and our IDX billing system. This allows the identification of potential patient cohorts based on demographics, procedures, diagnoses, and medications. In addition, by integration with drug characteristic information derived from NDFRT and RxNorm, higher level drug classifications can be used for cohort identification as well. The resource can also be used to search for inappropriate co-occurrences of specific entities in patient records to drive clinical quality improvement. Mining of these data can also identify markers of risk in the context of outcomes research.
Biography: Dr. Richard Scheuermann received his B.S. degree in Life Sciences from the Massachusetts Institute of Technology and his Ph.D. degree in Molecular Biology from the University of California, Berkeley, and joined the faculty at UT Southwestern Medical Center (Dallas, TX) in 1992. He is on the Scientific Advisory Boards of the Gene Ontology Consortium and Lead Horse Technologies, and is an OBO Foundry Coordinator. His recent research focus has been in the development of new algorithms for the analysis of gene expression microarray, genetic, flow cytometry and biological network data, and in the development of approaches and standards for biological knowledge representation. Dr. Scheuermann and his group are leading three large database development projects funded by the U.S. NIH – the Influenza Research Database (www.fludb.org), the Virus Pathogen Bioinformatics Resource Center (www.viprbrc.org) and the Immunology Database and Analysis Portal (www.immport.org). Dr. Scheuermann also serves as the Biomedical Informatics Key Function Lead for UT Southwestern’s Clinical and Translational Science Award (CTSA).
Health Outcomes and Epidemiology Perspective
Matthew Samore, M.D., VA Salt Lake City Health Care System, Professor, Division of Epidemiology, University of Utah; Linked Health Data Foundation Board of Directors
Biography: Professor of Medicine, Adjunct Professor of Biomedical Informatics. Dr. Samore is the Director of the Salt Lake IDEAS Center and Chief of the Division of Epidemiology at the University of Utah. He attended the University of Wisconsin School of Medicine, completed his residency in Internal Medicine at Washington University in St. Louis, and his Fellowship in Infectious Diseases at Brigham and Women's Hospital and Beth Israel Hospital in Boston. Dr. Samore was a member of the faculty of Harvard Medical School for 8 years. His research mentors included Drs. Jonathan Freeman, Mark Roberts, Richard Platt, Donald Goldmann, and AW Karchmer. Dr. Samore’s expertise encompasses epidemiologic methods, computer-based surveillance, and decision support systems. Dr. Samore has spearheaded program building efforts in health services research at the VA Salt Lake City Health Care System and University of Utah. He has broad-based experience in leading inter-disciplinary research programs. He is a member of the HSR&D Scientific Review and Evaluation Board (SREB), Subcommittee for Career Development and of the Agency for Health Care Research and Quality (AHRQ) Health Care Research Training (HCRT) Study Section.
This digital course provides special footage of all Bio-IT Keynote Sessions. The Tuesday and Wednesday Keynote presentations offered vivid examples of the current and future impact of technology in data for research and drug discovery opportunities. Also included as part of the Wednesday Keynote material is The Benjamin Franklin Award presentation. The Benjamin Franklin Award is given to an individual who has, in his or her practice, promoted free and open access to the materials and methods used in the life sciences. The Thursday Keynote panel featured a series of succinct, forward looking presentations. Special guest speakers shared their unique perspective on the future challenges facing the research, pharma, and medical communities.
Making the World’s Knowledge Computable
Stephen Wolfram, Ph.D., CEO, Wolfram Research; Creator of Wolfram\Alpha
Interacting with Complex Information Landscapes: Integration and Next Generation User Interfaces
Bryn Roberts, Ph.D., Global Head, Informatics, Pharma Research and Early Development, F. Hoffmann-La Roche
Benjamin Franklin Award & Presentation
Jonathan Eisen, Ph.D., Professor, Genome Center, University of California, Davis
Keynote Panel Chairperson
Kevin Davies, Editor-in-Chief, Bio-IT World
Pharma Futurology: 2016 and Beyond
Yury Rozenman, Global Head of Marketing, Pharmaceutical and Life Sciences Sector, BT Global Sciences
Global Risk Informatics: The Application of High Performance Computing to Public Health
Debra Goldfarb, Senior Director, Strategy, Microsoft
Ecosystem-Driven Approaches for 21st Century Biomedicine
Ken Buetow, Ph.D., Associate Director for Bioinformatics and Information Technology, National Cancer Institute
Integration of Real Time Discovery and Clinical Care
Ben Heywood, Co-founder and Chairman, PatientsLikeMe
The Goody-Gaga Effect: Health Communication at the Nexus of Social Media and Popular CultureMark Boguski, M.D., Ph.D., Founder, Resounding Health Incorporated
Gaming in the Workplace
Martin D. Leach, Ph.D., Executive Director, MRL IT for Discovery & Pre-Clinical Sciences, Merck & Co.
About the Conference:
Bio-IT World Conference & Expo
Enabling Technology. Leveraging Data. Transforming Medicine.
Since its debut in 2002, the annual Bio-IT World Conference & Expo (www.bio-itworldexpo.com) has established itself as a premier event showcasing the myriad applications of IT and informatics to biomedical research and the drug discovery enterprise. The Conference attracts a highly influential audience consisting of senior level scientists, IT professionals and Executives from organizations across the life sciences industry including Pharmaceutical, Biotechnology, Health Systems, Academia, Government and National Laboratories. In 2011, over 2,000 delegates gathered from 29 countries to share information and discuss enabling technologies that are driving the drug discovery process and transforming medicine. The event features concurrent tracks with 160+ technology and scientific presentations.